Trial Profile
A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Hafnium oxide (Primary) ; Nivolumab; Pembrolizumab
- Indications Bladder cancer; Cancer metastases; Cervical cancer; Gastric cancer; Head and neck cancer; Liver cancer; Liver metastases; Lung cancer; Malignant melanoma; Merkel cell carcinoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
- Focus Adverse reactions; First in man
- Sponsors Nanobiotix
- 05 Dec 2023 Planned End Date changed from 30 Mar 2028 to 30 May 2028.
- 26 Sep 2023 According to a Nanobiotix media release, Phase 1 data update anticipated between 2H 2023 and 1H 2024.
- 26 Sep 2023 According to a Nanobiotix media release, initial Phase 1 dose escalation safety data in pancreatic cancer from ongoing collaboration with MD Anderson is expected before the end of this year.